Introduction: Sustained opioid use has long-term negative impacts on future pain experience, particularly in women. This study aimed to investigate the underlying spinal neurobiology of this clinical observation in an experimental model of joint pain.
Objectives: In this study, we tested the hypothesis that sustained opioid treatment exacerbates chronic pain responses and alters spinal cord dorsal horn astrogliosis and the expression of GluN2B-containing N-methyl-d-aspartate receptors in female rats.
Methods: Subcutaneous morphine (3 mg/kg) or saline was administered twice daily for 1 week before inducing a model of joint knee pain (intra-articular injection of 2 mg of monosodium iodoacetate [MIA]) in adult female Sprague-Dawley rats, with pain-free controls receiving 50 µL of saline. Pain behavior (weight-bearing and mechanical paw withdrawal thresholds) was measured at baseline and at intervals thereafter. Twice-daily morphine/saline treatment was continued for up to 3 weeks after intra-articular injections, and spinal cord tissue was collected for Western blot analyses.
Results: Area under the curve analysis of weight-bearing asymmetry confirmed a significant exacerbation of pain behavior in the morphine/MIA group, compared with the saline/MIA group (F = 46.3, < 0.0001), despite comparable joint damage in both groups. Sustained morphine treatment was associated with significant elevations in dorsal horn expression of astrocytic glial fibrillary acidic protein (27 ± 5% increase) and neuronal GluN2B (80 ± 30% increase), but not microglial IBA1, irrespective of the model of joint pain.
Conclusion: These data suggest that sustained morphine treatment in female rats drives spinal cord plasticity, including spinal astrogliosis and the expression of GluN2B-containing N-methyl-d-aspartate receptors, priming the dorsal horn to incoming sensory inputs and producing exacerbated pain responses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10936964 | PMC |
| http://dx.doi.org/10.1097/PR9.0000000000001145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effects of low-dose morphine on sleep and breathlessness in COPD: A randomized trial.
Chest
December 2024
Flinders Health and Medical Research Institute/Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia.
Background: Low-dose morphine may be prescribed to reduce chronic breathlessness in chronic obstructive pulmonary disease (COPD). Recent subjective findings suggest morphine may influence breathlessness through sleep-related mechanisms. However, concerns exist regarding opioid safety in COPD.
View Article and Find Full Text PDFThe cannabinoid CB agonist LY2828360 suppresses neuropathic pain behavior and attenuates morphine tolerance and conditioned place preference in rats.
Neuropharmacology
December 2024
Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA; Gill Institute for Neuroscience, Indiana University, Bloomington, IN, USA. Electronic address:
Cannabinoid CB agonists show promise as analgesics because they lack unwanted side effects associated with direct activation of CB receptors. CB receptor activation suppresses pathological pain in animal models, but the types of pain that best respond to CB agonists are incompletely understood. This gap in knowledge may contribute to failures in clinical translation.
View Article and Find Full Text PDFChallenges for the implementation of injectable opioid agonist treatment: a scoping review.
Harm Reduct J
December 2024
Addiction Competence Centre, Austrian National Public Health Institute (Gesundheit Österreich GmbH, GOEG), Vienna, Austria.
Article Synopsis
- - The study explores the implementation of injectable opioid agonist treatment (iOAT) with diacetylmorphine and hydromorphone, aiming to identify key barriers and facilitators impacting its success.
- - A systematic review of 44 articles reveals barriers such as public acceptance issues, legal challenges, negative media portrayals, and high costs, alongside regulatory constraints faced by patients and providers.
- - Facilitators for effective iOAT include integrating treatments into broader drug policies, publishing supportive data for public discussion, and ensuring ethical compliance through dedicated committees.
Differences in uni-dimensional breathlessness measures and thresholds for clinical response in a randomised controlled trial in people with chronic breathlessness: an exploratory study.
BMJ Open Respir Res
December 2024
University of Wollongong Faculty of Science Medicine and Health, Wollongong, New South Wales, Australia
Article Synopsis
- This study examined how well different measures assess improvements in chronic breathlessness during clinical practice and research, particularly focusing on patients with chronic obstructive pulmonary disease.
- A total of 284 elderly men with severe chronic breathlessness participated, and findings indicated that certain measures were more effective in tracking improvements, while others provided similar responses.
- The results emphasized that assessing the worst breathlessness experienced may be crucial, and highlighted that recall timeframe and thresholds for meaningful improvement significantly impact the evaluation of breathlessness.
Increasing Access to Palliative Care in Cameroon: Progress, Gaps, and Recommendations.
Nurs Rep
November 2024
Palliative Care Unit, Cameroon Baptist Convention Health Services, Tiko P.O. Box 152, Cameroon.
Background/objectives: Access to palliative care is an urgent global need. Countries with the greatest palliative care needs have limited access. In Cameroon, demand for palliative care is growing due to the rising incidence of life-limiting conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!